Safety Evaluation of Adverse Reactions in Diabetes

Trial Profile

Safety Evaluation of Adverse Reactions in Diabetes

Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Exenatide (Primary) ; Gliclazide (Primary) ; Linagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms SAFEGUARD
  • Most Recent Events

    • 06 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 13 Jun 2017 Results (n=32) presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 23 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top